Gyre Therapeutics (GYRE) Cost of Revenue (2020 - 2026)

Gyre Therapeutics (GYRE) has 7 years of Cost of Revenue data on file, last reported at $14.1 million in Q1 2026.

• Quarterly Cost of Revenue rose 1481.21% year-over-year to $14.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $92.5 million (up 179.16% YoY) and the FY2025 annual result came in at $65.2 million, up 13.33% from the prior year.
• Cost of Revenue eased to $14.1 million in Q1 2026 per GYRE's latest filing, from $61.5 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $61.5 million in Q4 2025 and bottomed at $798000.0 in Q1 2022.
• The 5-year median for Cost of Revenue is $1.6 million (2025), against an average of $13.5 million.
• The widest annual swing landed in 2022, when Cost of Revenue surged 2077.67%; it then plunged 97.66% in 2023.
• Tracing GYRE's Cost of Revenue over 5 years: stood at $53.4 million in 2022, then tumbled by 97.66% to $1.2 million in 2023, then soared by 1248.48% to $16.9 million in 2024, then jumped by 264.89% to $61.5 million in 2025, then tumbled by 77.02% to $14.1 million in 2026.
• Per Business Quant, the three latest GYRE Cost of Revenue figures stand at $14.1 million (Q1 2026), $61.5 million (Q4 2025), and $1.6 million (Q3 2025).

Peer Comparison